Oshiro Satoshi, Minema Hirotaka, Shiroma Naohide, Hirayasu Kyoumi, Nakada Yukikatu
Department of Pediatrics, Okinawa Seishi Ryogoen, Naha, Okinawa.
No To Hattatsu. 2004 Jan;36(1):70-4.
We followed up 5 patients with subacute sclerosing panencephalitis (SSPE) for 14 to 81 months. They were treated with alpha-interferon (INF-alpha) and oral inosinpranobex (INP) in an early stage of Jabbour stage II and within 5 months after the onset. On admission, Ommaya reservoir was implanted for the intrathecal administration of INF-alpha. The dose was 1 x 10(5) U/m2 initially and daily increased to 1 x 10(6) U/m2. A total dose of 30 x 10(6) U/m3 was given to them over a 4-weeks to 6-weeks period. After discharge, a dose of 15 x 10(6) U/m2 in three patients was given weekly and a dose of 30 x 10(6) U/m2 in the other patients. In addition, all patients received oral INP. One patient showed mild progression and remained in early stage of Jabbour stage II. In the remaining 4 patients, the disease progressed to Jabbour stage III. Despite the small number of patients studied here, the results suggest that treatment with INF-alpha plus oral INP is ineffective in an early stage of SSPE.
我们对5例亚急性硬化性全脑炎（SSPE）患者进行了14至81个月的随访。他们在Jabbour II期早期且发病后5个月内接受了α-干扰素（INF-α）和口服异丙肌苷（INP）治疗。入院时，植入了Ommaya贮器用于鞘内注射INF-α。初始剂量为1×10⁵ U/m²，每日增加至1×10⁶ U/m²。在4至6周的时间内，他们总共接受了30×10⁶ U/m³的剂量。出院后，3例患者每周接受15×10⁶ U/m²的剂量，其他患者接受30×10⁶ U/m²的剂量。此外，所有患者均接受口服INP治疗。1例患者病情出现轻度进展，仍处于Jabbour II期早期。其余4例患者病情进展至Jabbour III期。尽管此处研究的患者数量较少，但结果表明，INF-α联合口服INP治疗在SSPE早期无效。
